Src/c-Abl Pathway Inhibitor for ALS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for amyotrophic lateral sclerosis (ALS) are limited, and existing kinase inhibitors targeting multiple kinases do not clearly specify which pathway is responsible for their anti-ALS activity, making it challenging to develop effective treatments regardless of the causative gene.
Innovation Solution
The development of a Src/c-Abl pathway inhibitor, such as bosutinib, which targets the Src/c-Abl pathway in motor neurons derived from ALS patients, promoting autophagy and reducing the accumulation of misfolded proteins, thereby increasing survival rates and prolonging survival in ALS model mice.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple kinase inhibitors are used to target various signal transduction pathways, then anti-ALS activity is observed, but it remains unclear which specific pathway or kinase inhibition achieves the therapeutic effect
Solution Approach 1:
The patent segments the broad kinase inhibition approach into a specific focus on the Src/c-Abl pathway. By narrowing the target to this specific pathway, the invention resolves the information loss about which pathway is responsible for anti-ALS activity while maintaining therapeutic effectiveness through targeted inhibition of Src and c-Abl kinases.
2Ease of manufacture
If existing drugs with confirmed safety in human are used for ALS treatment, then development cost is reduced and practicalization is accelerated, but the therapeutic efficacy for ALS must be demonstrated through new mechanisms
Solution Approach 1:
The patent applies drug repositioning by identifying Src/c-Abl pathway inhibitors (such as bosutinib, dasatinib, imatinib) that have existing safety profiles from their original indications (cancer therapy) and demonstrating their efficacy for ALS treatment. This multi-functional use of existing drugs accelerates development while maintaining therapeutic reliability through mechanism-based validation.
3Reliability
If kinase inhibitors are used to treat ALS, then motor neuron survival is improved, but the complexity of identifying the correct target pathway increases
Solution Approach 1:
The patent changes the parameter of target specificity from broad kinase inhibition to focused Src/c-Abl pathway inhibition. This parameter change simplifies the complexity of target identification by establishing a clear mechanistic focus on Src and c-Abl kinases, thereby improving motor neuron survival through targeted therapy without the complexity of screening multiple pathways.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Src/c-Abl pathway inhibitor effectively treats various forms of ALS, including familial and sporadic cases, by specifically targeting the Src/c-Abl pathway, enhancing motor neuron survival and delaying disease progression, and can be rapidly developed into a pharmaceutical product due to existing safety data from other medications.
Implementation Method 1
promoting autophagy and reducing the accumulation of misfolded proteins
Data Source
AI summary
The present invention provides a prophylactic and/or therapeutic agent for ALS containing a Src/c-Abl pathway inhibitor.